ArticleOpen forum infectious diseases2026
Voriconazole as a Secondary Prophylaxis for Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation: Real-world Evidence From a Major Transplantation Center in Taiwan.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Voriconazole plays an important role in the treatment of invasive fungal infections (IFIs). Keeping voriconazole concentration at appropriate levels is crucial for drug effectiveness and safety. However, it remains unclear whether drug concentrations influence the clinical outcome of secondary prophylaxis in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: In this retrospective analysis, 83 patients receiving allo-HSCT with histories of IFIs responsive to voriconazole were enrolled. These patients continued voriconazole during and after allo-HSCT. Their characteristics, clinical outcomes, and plasma voriconazole concentrations at (1) Days -30 to -9, (2) Days -8 to -1, (3) Days 0 to 14, and (4) Days 15 to 30 of allo-HSCT were examined. Results: Voriconazole trough concentrations significantly declined after transplantation and remained low for approximately 4 weeks post allo-HSCT, despite dose adjustment. This variation was observed across subgroups defined by age, sex, diagnosis, conditioning regimens, donor type, administration route, or documented drug interactions. The cumulative incidence of breakthrough IFI was 11.4% at 3 months and 18.6% at 1 year after transplantation. Transient decreases in voriconazole trough levels were not significantly associated with breakthrough IFIs. However, a trend toward a lower risk of proven or probable breakthrough IFIs at 12 months has been observed in patients having average voriconazole trough levels ≥ 1 mg/L after allo-HSCT. Conclusions: Transient fluctuations in voriconazole levels occur after allo-HSCT, independent of most clinical factors. These subtherapeutic exposures did not significantly affect the incidence of breakthrough IFIs in this cohort. Larger prospective studies are warranted to further investigate the clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.